Humacyte, Inc. (HUMA): Price and Financial Metrics


Humacyte, Inc. (HUMA): $5.50

0.39 (+7.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HUMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HUMA Stock Price Chart Interactive Chart >

Price chart for HUMA

HUMA Price/Volume Stats

Current price $5.50 52-week high $17.45
Prev. close $5.11 52-week low $4.26
Day low $4.94 Volume 306,700
Day high $5.61 Avg. volume 408,376
50-day MA $6.37 Dividend yield N/A
200-day MA $8.39 Market Cap 566.53M

Humacyte, Inc. (HUMA) Company Bio


Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded in 2004 and is based in Durham, North Carolina.


HUMA Latest News Stream


Event/Time News Detail
Loading, please wait...

HUMA Latest Social Stream


Loading social stream, please wait...

View Full HUMA Social Stream

Latest HUMA News From Around the Web

Below are the latest news stories about Humacyte Inc that investors may wish to consider to help them evaluate HUMA as an investment opportunity.

Humacyte to Participate in Fireside Chat at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

DURHAM, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a virtual fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 15, 2022, at 9 a.m. EST. The webcast will

Yahoo | February 9, 2022

Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios

– Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society – – HAV observed to maintain patency and resist infection in the treatment of critical limb ischemia, infection and vascular trauma – – All patients lacked suitable alternative conduit options – DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioe

Yahoo | January 31, 2022

Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting

-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass surgery -- -- Results presented at Advanced Therapies Week 2022 -- DURHAM, N.C., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced result

Yahoo | January 28, 2022

Humacyte (NASDAQ:HUMA) shareholders have endured a 47% loss from investing in the stock a year ago

The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

Yahoo | January 25, 2022

Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatment of Critical Limb Ischemia at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society

DURHAM, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that results from the first series of compassionate use cases of Humacyte’s Human Acellular VesselTM (HAV) will be presented at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society (VESS) in Snowmass, Colo. at 7:56 a.m. MST on January 28, 2022. Th

Yahoo | January 6, 2022

Read More 'HUMA' Stories Here

HUMA Price Returns

1-mo -22.32%
3-mo -8.79%
6-mo -49.22%
1-year -44.67%
3-year N/A
5-year N/A
YTD -24.14%
2021 -28.71%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6069 seconds.